Tandem Diabetes Care Conference Call Summary Company Overview - **Company**: Tandem Diabetes Care (NasdaqGM:TNDM) - **Date**: September 10, 2025 - **Speakers**: CEO John Sheridan, CFO Leigh Vosseller Key Points Industry and Market Dynamics - Tandem Diabetes Care is undergoing a transformation aimed at driving double-digit growth and profitability starting next year and beyond [2][5] - The company is focusing on a multi-channel access strategy, particularly expanding into the pharmacy channel, which offers lower out-of-pocket costs for patients and easier prescription processes for physicians [2][3] - The type 2 diabetes market presents a significant opportunity, potentially doubling the available market in the U.S. with approximately 2.3 million people requiring insulin-intensive treatment [12][13] Financial Performance and Strategy - Approximately 30% of U.S. lives are currently covered under pharmacy contracts, with expectations to increase coverage significantly in the next two to three years [7][11] - The company aims for a gross margin of 60% by the end of 2026, with a focus on improving profitability through increased supply sales and reduced manufacturing costs [28][22][25] - Recurring revenue from supply sales and renewals is becoming a larger part of the revenue base, providing predictability and driving growth [22][23] Product Pipeline and Innovations - Tandem has an exciting product pipeline, including the Tandem Mobi system and upcoming Tubeless Mobi system, which are designed to meet diverse patient needs [5][42][44] - The SteadySet infusion set, which allows for extended wear of up to seven days, has received FDA approval and is expected to enhance the customer experience [46] - Control-IQ technology continues to be a competitive advantage, with recent improvements aimed at simplifying user interaction and enhancing diabetes management [49][50] Competitive Landscape - The diabetes management market is becoming increasingly competitive, with new entrants expected to create turbulence. However, Tandem believes that competition drives innovation and benefits patients [17][20] - The company is prepared to leverage its superior algorithm and product offerings to capture market share, particularly in the underpenetrated type 2 diabetes segment [15][48] International Expansion - Tandem plans to expand its direct sales operations in certain international markets starting January 1, 2026, aiming to improve sales effectiveness and capture more market share [3][34][36] - The company operates in about 25 countries outside the U.S., with significant growth potential due to low penetration rates [39][41] Operational Improvements - The company is focused on enhancing operational efficiency through automation and improved sales processes, which are expected to contribute to margin improvements [26][30] - Recent expansions in the commercial team are aimed at increasing productivity and effectiveness in the sales organization [3][32] Conclusion - Tandem Diabetes Care is positioned for significant growth through strategic expansion into the pharmacy channel, innovative product offerings, and operational efficiencies. The company is optimistic about its future prospects in both the U.S. and international markets, particularly in the type 2 diabetes segment.

Company Overview - Glucotrack, Inc. is a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes [5] - The company is developing a long-term implantable continuous blood glucose monitoring system [5][6] Product Details - Glucotrack's Continuous Blood Glucose Monitor (CBGM) is designed to measure blood glucose levels directly from the blood, without the need for on-body wearables, and has a sensor longevity of up to three years [3][6] - The CBGM aims to minimize daily disruptions for diabetes patients by addressing limitations of traditional continuous glucose monitors (CGM), such as frequent sensor changes and challenges associated with on-body wearables [3] Upcoming Events - Glucotrack will participate in the 2025 Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting from August 8-11, 2025, in Phoenix, AZ [1] - The company will showcase its CBGM at Booth 1724 and present a poster on physician perspectives regarding continuous blood glucose monitoring technology [2][3]

Core Viewpoint - Medtronic plc has appointed Chad Spooner as the chief financial officer (CFO) of MiniMed, ahead of its planned separation into a standalone public company, effective July 14, 2025 [1][5]. Company Overview - Medtronic is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [8]. - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions through various technologies and therapies [8]. Leadership Appointment - Chad Spooner brings over 25 years of financial leadership experience in healthcare, consumer, and industrial sectors, previously serving as CFO at BIC and holding senior finance roles at General Electric and other companies [2][4]. - His appointment is seen as crucial for driving transformation and growth as MiniMed prepares for independence [3][4]. MiniMed Separation - Medtronic announced that MiniMed will be the name of the new standalone company, honoring its 40-year legacy in diabetes care [3]. - The separation is expected to be completed within 18 months of the initial announcement, subject to customary conditions and legal requirements [5]. Mission and Vision - MiniMed's mission is to make diabetes management more predictable, enhancing the lives of individuals with diabetes through advanced technology and support [7].

Core Insights - Medtronic has received FDA approval for the Simplera Sync™ sensor, enhancing the MiniMed™ 780G system's capabilities in the U.S. market [1][3] - The Simplera Sync™ sensor is a disposable, all-in-one device that eliminates the need for fingersticks and simplifies the insertion process, providing greater flexibility for users [2][6] - The MiniMed™ 780G system features an adaptive algorithm that adjusts glucose levels every 5 minutes, utilizing Meal Detection™ technology to optimize insulin delivery [2][3] Product Features - The Simplera Sync™ sensor is designed to work seamlessly with the MiniMed™ 780G system, which can now utilize both the Guardian™ 4 sensor and the new Simplera Sync™ sensor [1][3] - The system allows for flexible glucose targets as low as 100 mg/dL and has shown real-world data indicating users achieve over 70% time in range when using optimal settings [2][6] - The MiniMed™ 780G system is the only one that can be paired with an infusion set lasting up to 7 days, significantly reducing the frequency of injections [2][6] Company Commitment - Medtronic is dedicated to innovating diabetes management technologies to improve the quality of life for individuals living with diabetes [3][4] - The company plans a limited launch of the Simplera Sync™ sensor in the U.S. in fall 2025, further expanding its CGM options [3][4] - Medtronic has a long history of pioneering diabetes technology and aims to continue leading in this field through advanced sensors and intelligent dosing systems [4][5]

Core Insights - DexCom, Inc. has introduced new data for its G7 15-day continuous glucose monitoring (CGM) sensor, showcasing a mean absolute relative difference (MARD) of 8.0%, positioning it as the most accurate CGM in the market [1] - The G7 sensor's extended wear time and enhanced connectivity are expected to revolutionize diabetes management, particularly for Type 2 diabetes patients [3][4] - The company anticipates FDA approval for the G7 sensor by the second quarter of 2025, with a potential launch in the latter half of the year [5] Product Features and Market Position - The G7 sensor offers a 15-day wear duration, an improvement over the previous 10-day version, which reduces replacement frequency and overall costs for users [4] - DexCom is recognized as the most connected CGM brand globally, with new integration capabilities for devices like Omnipod 5 and NovoPen [10] - The company is leading the CGM market by driving innovation, expanding insurance coverage, and advocating for broader access to diabetes technology [3] Industry Trends and Healthcare Professional Insights - A survey indicates that 52% of healthcare professionals believe CGMs and diabetes education will be more crucial than new medications in managing Type 2 diabetes over the next decade [6] - There is strong support among healthcare professionals for CGM access among insulin users, with 96% advocating for multiple daily insulin injection users to have access [7] - Despite increasing recognition of CGMs, challenges such as funding constraints and restrictive eligibility criteria remain [8] Insurance Coverage and Accessibility - Insurance coverage for CGMs in the U.S. is improving, especially for intensive insulin users, with private insurers beginning to extend coverage to non-insulin users [9] - Medicare currently restricts CGM coverage to insulin users, but advocacy efforts may lead to policy changes in the future [9]